These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 3814034)

  • 21. Control of simulator sickness in an AH-64 aviator.
    Kroll JD
    Aviat Space Environ Med; 1989 Dec; 60(12):1202-3. PubMed ID: 2604677
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of transcutaneous scopolamine and depth on diver performance.
    Williams TH; Wilkinson AR; Davis FM; Frampton CM
    Undersea Biomed Res; 1988 Mar; 15(2):89-98. PubMed ID: 3363755
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Scopolamine plaster caused hallucination. Toxic psychosis in a 10-year-old boy caused by an agent against motion sickness].
    Björk M; Wettergren B
    Lakartidningen; 1995 Feb; 92(7):638. PubMed ID: 7861858
    [No Abstract]   [Full Text] [Related]  

  • 24. Transdermal scopolamine: human performance and side effects.
    Gordon C; Binah O; Attias J; Rolnick A
    Aviat Space Environ Med; 1986 Mar; 57(3):236-40. PubMed ID: 3964152
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antimotion-sickness efficacy of scopolamine 12 and 72 hours after transdermal administration.
    Graybiel A; Cramer DB; Wood CD
    Aviat Space Environ Med; 1982 Aug; 53(8):770-2. PubMed ID: 7181807
    [TBL] [Abstract][Full Text] [Related]  

  • 26. INM investigations into drugs for seasickness prophylaxis.
    Pingree BJ
    J R Nav Med Serv; 1994; 80(2):76-80. PubMed ID: 7707278
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of antimotion sickness drugs on habituation to motion.
    Wood CD; Manno JE; Manno BR; Odenheimer RC; Bairnsfather LE
    Aviat Space Environ Med; 1986 Jun; 57(6):539-42. PubMed ID: 3718377
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications.
    Nachum Z; Shupak A; Gordon CR
    Clin Pharmacokinet; 2006; 45(6):543-66. PubMed ID: 16719539
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of cinnarizine in the prevention of seasickness.
    Doweck I; Gordon CR; Spitzer O; Melamed Y; Shupak A
    Aviat Space Environ Med; 1994 Jul; 65(7):606-9. PubMed ID: 7945126
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of betahistine for the prevention of seasickness: effect on vestibular function, psychomotor performance and efficacy at sea.
    Gordon CR; Doweck I; Nachum Z; Gonen A; Spitzer O; Shupak A
    J Vestib Res; 2003; 13(2-3):103-11. PubMed ID: 14757913
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histaminergic response to Coriolis stimulation: implication for transdermal scopolamine therapy of motion sickness.
    Wang ET; Zhou DR; He LH
    Aviat Space Environ Med; 1992 Jul; 63(7):579-82. PubMed ID: 1616432
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transdermal scopolamine precipitating narrow-angle glaucoma.
    Fraunfelder FT
    N Engl J Med; 1982 Oct; 307(17):1079. PubMed ID: 7121520
    [No Abstract]   [Full Text] [Related]  

  • 33. Effects of scopolamine on autonomic profiles underlying motion sickness susceptibility.
    Uijtdehaage SH; Stern RM; Koch KL
    Aviat Space Environ Med; 1993 Jan; 64(1):1-8. PubMed ID: 8424733
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Seasickness in totally-enclosed motor-propelled survival craft: remedial measures.
    Landolt JP; Monaco C
    Aviat Space Environ Med; 1992 Mar; 63(3):219-25. PubMed ID: 1567325
    [TBL] [Abstract][Full Text] [Related]  

  • 35. I heard that the adhesive patch you can wear to prevent motion sickness is available again. Why was it taken off the market?
    Mayo Clin Health Lett; 1998 Mar; 16(3):8. PubMed ID: 9516375
    [No Abstract]   [Full Text] [Related]  

  • 36. [Transdermal therapeutic system of scopolamine (TTS-S) in the prevention of sea sickness and its mechanism of action].
    Wang E
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 1990 Oct; 25(5):299-302, 319. PubMed ID: 2076342
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical manifestations of transdermal scopolamine addiction.
    Luetje CM; Wooten J
    Ear Nose Throat J; 1996 Apr; 75(4):210-4. PubMed ID: 8935644
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Scopolamine withdrawal syndrome.
    Saxena K; Saxena S
    Postgrad Med; 1990 Jan; 87(1):63-6. PubMed ID: 2296571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of scopolamine and cyclizine on visual-vestibular interaction in humans.
    Gowans J; Matheson A; Darlington CL; Smith PF
    J Vestib Res; 2000; 10(2):87-92. PubMed ID: 10939683
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transdermal scopolamine for motion sickness.
    Med Lett Drugs Ther; 1981 Oct; 23(21):89-90. PubMed ID: 7027000
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.